Published in PLoS One on November 15, 2011
Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. J Pharm Sci (2015) 0.84
Determination of factors controlling the particle size and entrapment efficiency of noscapine in PEG/PLA nanoparticles using artificial neural networks. Int J Nanomedicine (2014) 0.79
The Noscapine Chronicle: A Pharmaco-Historic Biography of the Opiate Alkaloid Family and its Clinical Applications. Med Res Rev (2015) 0.77
Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non-small-cell Lung Cancer. Mol Ther Nucleic Acids (2016) 0.76
Formulation, Pharmacokinetic, and Efficacy Studies of Mannosylated Self-Emulsifying Solid Dispersions of Noscapine. PLoS One (2016) 0.75
Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. Exp Cell Res (2016) 0.75
Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm Res (2015) 0.75
Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst (1999) 8.59
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol (2007) 4.94
Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents (2002) 2.97
Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res (2004) 2.37
Managing taxane toxicities. Support Care Cancer (2002) 1.95
Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res (2004) 1.84
Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci U S A (1998) 1.84
Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer (2001) 1.75
Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol Ther (2005) 1.65
Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res (2005) 1.58
Role of formulation vehicles in taxane pharmacology. Invest New Drugs (2001) 1.58
Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol (2004) 1.42
Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol (2007) 1.37
Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res (2002) 1.37
Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol (2005) 1.36
Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer (2009) 1.30
Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist (2005) 1.28
Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol (1990) 1.23
Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem (2002) 1.22
Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett (2010) 1.22
p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res (2007) 1.20
Identification of novel and improved antimitotic agents derived from noscapine. J Med Chem (2005) 1.20
Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood (2005) 1.19
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer (1999) 1.19
Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer (2010) 1.17
Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res (2004) 1.16
Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol (2008) 1.16
Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis (2009) 1.14
Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res (2009) 1.12
Pharmacokinetic properties of noscapine. Eur J Clin Pharmacol (1982) 1.09
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg (2004) 1.09
Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer. PLoS One (2011) 1.07
Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur J Cancer (2001) 1.05
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther (2008) 1.00
Effect of noscapine and vincristine combination on demyelination and cell proliferation in vitro. Leuk Lymphoma (2008) 0.93
Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. Anticancer Drugs (2007) 0.92
Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther (2009) 0.90
Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer (2010) 0.89
Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab (2001) 0.87
Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. Br J Cancer (2005) 0.86
Challenging the platinum combinations in the chemotherapy of NSCLC. Lung Cancer (2002) 0.84
Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy? Curr Hematol Malig Rep (2010) 0.83
Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors. Int J Radiat Oncol Biol Phys (2008) 0.83
Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil. Invest New Drugs (2008) 0.82
Current and emerging therapies for patients with advanced non-small-cell lung cancer. Am J Health Syst Pharm (2010) 0.81
Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways. J Carcinog (2006) 0.76
[Gemcitabine: a new chemotherapy agent for solid cancers]. Rev Med Brux (1997) 0.76
Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol (2010) 1.51
Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother (2011) 1.25
Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer (2010) 1.17
Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol (2008) 1.16
Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res (2009) 1.12
Evaluation of different parameters that affect droplet-size distribution from nasal sprays using the Malvern Spraytec. J Pharm Sci (2004) 1.11
Box-Behnken experimental design in the development of a nasal drug delivery system of model drug hydroxyurea: characterization of viscosity, in vitro drug release, droplet size, and dynamic surface tension. AAPS PharmSciTech (2005) 1.07
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. Bioorg Med Chem (2008) 1.07
Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer. PLoS One (2011) 1.07
In vitro and in vivo evaluation of topical formulations of spantide II. AAPS PharmSciTech (2005) 1.06
Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release (2010) 1.05
AlgiMatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One (2013) 1.03
Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm Res (2006) 1.01
Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma. Clin Cancer Res (2004) 0.99
Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer. Mol Cancer Ther (2010) 0.98
Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J Control Release (2012) 0.96
15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anticancer Drugs (2007) 0.95
Effect of oleic acid modified polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen. J Control Release (2011) 0.94
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer (2006) 0.92
Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release (2013) 0.91
Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: spantide II. Pharm Res (2004) 0.90
Effect of vehicles on the transdermal delivery of melatonin across porcine skin in vitro. J Control Release (2002) 0.90
Skin permeation enhancement effect and skin irritation of saturated fatty alcohols. Int J Pharm (2002) 0.90
Dermal microdialysis technique to evaluate the trafficking of surface-modified lipid nanoparticles upon topical application. Pharm Res (2012) 0.87
Evaluation of the Malvern Spraytec with inhalation cell for the measurement of particle size distribution from metered dose inhalers. J Pharm Sci (2004) 0.86
Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers. Antimicrob Agents Chemother (2013) 0.85
Formulation and in vitro evaluation of transdermal patches of melatonin. Drug Dev Ind Pharm (2004) 0.85
Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J Control Release (2013) 0.85
1,1-Bis (3'-indolyl)-1-(p-substitutedphenyl)methane compounds inhibit lung cancer cell and tumor growth in a metastasis model. Eur J Pharm Sci (2013) 0.84
Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation. Mol Pharm (2015) 0.84
Effect of cyclodextrins on the complexation and nasal permeation of melatonin. Drug Deliv (2008) 0.83
Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. J Pharm Pharmacol (2004) 0.81
Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats. Pharmacol Biochem Behav (2012) 0.81
Inhalation delivery of anticancer agents via HFA-based metered dose inhaler using methotrexate as a model drug. J Aerosol Med (2002) 0.81
Chemoprevention of skin cancer with 1,1-Bis (3'-indolyl)-1-(aromatic) methane analog through induction of the orphan nuclear receptor, NR4A2 (Nurr1). PLoS One (2013) 0.80
Effect of monensin liposomes on the cytotoxicity of anti-My9-bR immunotoxin. J Pharm Pharmacol (2003) 0.80
Identification and Testing of Novel CARP-1 Functional Mimetic Compounds as Inhibitors of Non-Small Cell Lung and Triple Negative Breast Cancers. J Biomed Nanotechnol (2015) 0.80
EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer. Pharm Res (2014) 0.80
In vitro and in vivo comparison of dermal irritancy of jet fuel exposure using EpiDerm (EPI-200) cultured human skin and hairless rats. Toxicol Lett (2006) 0.79
Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm Res (2013) 0.79
Estimation of proinflammatory biomarkers of skin irritation by dermal microdialysis following exposure with irritant chemicals. Toxicology (2007) 0.78
Dermal microdialysis of inflammatory markers induced by aliphatic hydrocarbons in rats. Toxicol Lett (2008) 0.78
Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine (Lond) (2014) 0.78
Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. J Drug Target (2011) 0.78
Brownian diffusion and surface kinetics of liposome and viral particle uptake by human lung cancer cells in-vitro. Ann Biomed Eng (2006) 0.78
Epithelial transport of noscapine across cell monolayer and influence of absorption enhancers on in vitro permeation and bioavailability: implications for intestinal absorption. J Drug Target (2014) 0.77
Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3' diindolylmethane (DIM). Eur J Pharm Sci (2012) 0.77
Opening up the optical imaging window using nano-luciferin. Pharm Res (2014) 0.77
Effect of jet fuels on the skin morphology and irritation in hairless rats. Toxicology (2002) 0.77
Unique Aspects of Coronary Artery Disease in Indian Women. Cardiovasc Drugs Ther (2015) 0.77
Enhanced Percutaneous Delivery of 1,1-bis(3'-indolyl)-1-(p-chlorophenyl) Methane for Skin Cancer Chemoprevention. J Biomed Nanotechnol (2015) 0.76
Chapter 9 - Nanoliposomal dry powder formulations. Methods Enzymol (2009) 0.76
Passive droplet sorting using viscoelastic flow focusing. Lab Chip (2013) 0.76
Evaluation of Spray BIO-Max DIM-P in Dogs for Oral Bioavailability and in Nu/nu Mice Bearing Orthotopic/Metastatic Lung Tumor Models for Anticancer Activity. Pharm Res (2015) 0.76
Stability and degradation profiles of Spantide II in aqueous solutions. Eur J Pharm Sci (2005) 0.76
Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line. J Pharm Pharmacol (2004) 0.75
'Doubling up' procedures in a protocol amendment. Too many problems. Lab Anim (NY) (2011) 0.75
Effect of combination of hydrophilic and lipophilic permeation enhancers on the skin permeation of kahalalide F. J Pharm Pharmacol (2014) 0.75
Evaluation of metered dose inhaler (MDI) formulations of ciclosporin. J Pharm Pharmacol (2007) 0.75
Primary pleuropulmonary synovial sarcoma with brain metastases in a paediatric patient: an unusual presentation. Adv Respir Med (2017) 0.75
Steep atomic dispersion induced by velocity-selective optical pumping. Opt Express (2008) 0.75
A rare complication in a case of multiple myeloma on therapy with thalidomide and dexamethasone--reversible posterior lobe leukoencephalopathy. Leuk Lymphoma (2006) 0.75
Spontaneous deep venous thrombosis: An unrecognized entity with sorafenib. J Cancer Res Ther (2016) 0.75